fashion -WSS

fashion

author：Wikipedia 2025-10-01 00:46:45 - browse：879

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Ukraine and a new approach to mental health in war

WSS

How housing is health care on Long Island

Private equity could exacerbate cardiology's overuse problem, experts fear

Senate HELP committee spars over health care workforce policies

Walmart eyes Medicare Advantage provider ChenMed

Regeneron agrees to White House price limits on anti

New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

fashion

leisure time

Peter Hotez and the public health issue of online harassment

Pig kidney works a record two months in donated body

The cancer drug shortage isn’t new — and neither are the solutions

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

In age of alternative facts, a scholarly course on calling out crap

What to make of Biden’s latest efforts on cancer research

As demand for Covid shots wanes, Moderna seeks its next success

FDA proposes changes to key medical devices approval pathway

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Intarcia’s device

explore

Medical student insurance fails on mental health care coverage

Lasker Awards 2023: Winners in biomedical research

FDA panel to weigh approval of NurOwn, controversial ALS drug

Second xenotransplant done with gene

How AI helped researchers track recovery from depression

Regeneron agrees to White House price limits on anti

explore

entertainment

entertainment

hotspot